Kisspeptin Research: What the Studies Show
Kisspeptin sits upstream of the entire reproductive axis: it acts directly on the hypothalamus to trigger gonadotropin-releasing hormone (GnRH) output, which in turn drives luteinising hormone (LH), follicle-stimulating hormone (FSH) and testosterone. That upstream position is why it has been studied in sexual desire disorders, hypothalamic amenorrhoea, PCOS and hypogonadism.
Mechanism of action
Kisspeptin binds the KISS1R (GPR54) receptor on GnRH neurons in the hypothalamus — the gatekeeping step for the whole hypothalamic-pituitary-gonadal axis.
Because it acts upstream of GnRH, it recruits the body's own pulsatile signalling rather than overriding it, producing physiological rises in LH, FSH and downstream sex steroids.
Beyond hormone output, imaging work shows kisspeptin modulates limbic and sexual-processing brain structures, which is the basis of the desire-disorder trials.
Loss-of-function mutations in KISS1R cause failure of puberty, which is the genetic evidence establishing kisspeptin as an essential gatekeeper of reproductive maturation.
The studies
All entries below are human clinical research. The desire-disorder trials are randomised, placebo-controlled and imaging-based; the intranasal work is early-phase delivery research; the final entry is an ongoing registry programme rather than a completed result.
Hypoactive sexual desire disorder
Male HSDD trial
Whether kisspeptin alters brain and physiological sexual response in men with hypoactive sexual desire disorder.
Double-blind placebo-controlled crossover · functional MRI during visual sexual stimuli · penile tumescence monitoring
- +56%
- Penile rigidity
- Modulated
- Brain activity
- Happier about sex
- Reported outcome
versus placebo, peak effect
sexual-processing network
- Kisspeptin significantly modulated activity in key structures of the sexual-processing network during visual sexual stimuli.
- Penile rigidity increased by up to 56% compared with placebo.
- Participants also reported psychological improvement — greater happiness about sex — alongside the physiological change.
Female HSDD trial
Whether kisspeptin safely alters sexual and attraction brain processing in premenopausal women with distressing low desire.
32 premenopausal women with HSDD · randomised, placebo-controlled · functional MRI during sexual and facial-attraction tasks
- 32
- Participants
- Modulated
- Brain processing
- Well tolerated
- Safety
premenopausal women
sexual & facial attraction
- Kisspeptin safely modulated sexual and facial-attraction brain processing under fMRI.
- Enhanced activity in those circuits correlated with reduced sexual aversion and associated distress.
- The trial established that the desire-disorder signal seen in men is not sex-specific.
Delivery research
Intranasal kisspeptin-54
Whether kisspeptin can stimulate gonadotropin release without injection.
Intranasal kisspeptin-54 · healthy volunteers and patients with hypothalamic amenorrhoea · serial gonadotropin sampling
- Intranasal
- Route
- Rapid & robust
- Gonadotropin response
- None reported
- Adverse effects
- Intranasal kisspeptin-54 produced rapid, robust stimulation of gonadotropin release, removing the need for injection.
- It worked in both healthy participants and patients with hypothalamic amenorrhoea.
- No adverse side effects were reported in the study population.
Safety & hormone optimisation
Anxiety and physiological impact trial
Whether a biologically active dose of kisspeptin triggers a stress or anxiety response.
Placebo-controlled administration · state anxiety scoring · serum LH, cortisol, blood pressure and heart rate monitoring
- Robustly raised
- Serum LH
- No change
- State anxiety
- No change
- Cortisol / BP / HR
- A biologically active dose robustly raised serum LH as expected.
- It caused no alteration in state anxiety, circulating cortisol, blood pressure or heart rate.
- This separates the reproductive effect from any stress-axis activation.
Adult reproductive axis baseline studies
Long-term dosing metrics in idiopathic hypogonadotropic hypogonadism (IHH) and polycystic ovarian syndrome (PCOS).
Ongoing NIH-registered programme · adult reproductive-axis characterisation · NCT00914823
- NCT00914823
- Registry ID
- IHH & PCOS
- Populations
- Ongoing
- Status
- A broad research umbrella tracking long-term dosing metrics rather than a single endpoint.
- Targets idiopathic hypogonadotropic hypogonadism and polycystic ovarian syndrome.
- Reinforces kisspeptin's role as a gatekeeper of puberty and fertility regulation. No final results are published yet.
Storage & handling
Kisspeptin-10 is supplied as a lyophilised powder. Keep sealed vials refrigerated or frozen, protected from light and moisture.
Reconstitute with bacteriostatic water directed slowly down the inner wall of the vial and swirl gently until clear. Do not shake.
Store reconstituted solution at 2-8 °C and use within the stability window set by your lab's standard operating procedures.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.